Navigation Links
Early Registration Deadline on Monday for U.S. Conference on Rare Diseases and Orphan Products
Date:9/13/2013

Horsham, PA (PRWEB) September 13, 2013

The early registration deadline for the third annual U.S. Conference on Rare Diseases and Orphan Products is Monday, Sept. 16. Co-sponsored by the National Organization for Rare Disorders (NORD) and DIA in collaboration with the Food and Drug Administration (FDA) and EURORDIS (Rare Diseases Europe), the conference will take place from Oct. 7 to 9 at the Bethesda North Marriott Hotel & Conference Center in Bethesda, Md.

Key stakeholders in the rare disease community, including patient advocates, industry leaders, researchers, regulatory officials and investors, will benefit from interactive plenary and group sessions focusing on topics such as legislative updates, scientific advances and the investment outlook.

Panels and speakers will include:

  •     Keynote speaker Bill Corr, deputy secretary, U.S. Department of Health and Human Services
  •     The Affordable Care Act and the Rare Disease Community, Catherine Oakar, senior policy adviser, U.S. Department of Health and Human Services
  •     The Investment Environment for Orphan Drugs/Devices, David I. Scheer, president, Scheer & Company, Inc.
  •     The International Perspective on Orphan Drugs/Devices, Geoffrey McDonough, M.D., president and CEO, Swedish Orphan Biovitrum AB (Sobi)
  •     Patients and Industry: Partnership and Collaboration in Research Funding and FDA Review, Kari Luther Rosbeck, president and CEO, Tuberous Sclerosis Alliance
  •     How Payer Organizations Make Coverage Decisions for Orphan Drugs, J. Russell Teagarden, senior vice president of medical and scientific affairs, NORD
  •     The Health Care System of the Future, William Shrank, M.D., assistant clinical professor of medicine, Harvard Medical School, and associate physician of the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital
  •     Managing Orphan Drug Recalls and Shortages, Pamela Williamson, senior vice president and global head of regulatory affairs and compliance, Genzyme, and Valerie Jensen, associate director of the Center for Drug Evaluation and Research, FDA
  •     Research Frontiers in Rare Diseases: The Next Opportunities, Anne Marie Finley, vice president of government relations and public policy, Celgene

Interact With Patient Advocates
Representatives of approximately 100 patient organizations will attend this year’s conference, providing opportunities for stakeholders to learn firsthand about patient needs and challenges and how to form partnerships to reach shared goals.

Register for the Conference Now
For more information or to register, visit the conference website. Early registration rates are available through Monday, Sept. 16. NORD and DIA have arranged for a discounted rate of $189 for a standard room at the Bethesda North Marriott Hotel & Conference Center. The rate is available until Sept. 23, or when the room block is filled. Follow instructions on the conference registration website for reserving a hotel room.

Attend the Pre-Conference FDA/EMA Orphan Product Designation and Grant Workshop

FDA and the European Medicines Agency (EMA) will co-host the FDA/EMA Orphan Product Designation and Grant Workshop on Oct. 4, at FDA’s White Oak Campus in Silver Spring, Md. The workshop will provide valuable information about the agencies’ orphan drug designation programs, the FDA Humanitarian Use Device designation program and the FDA Orphan Products Grants Program. There will be no registration fee for the workshop. For information and registration details, visit the FDA workshop website.

###

ABOUT NORD: NORD is a nonprofit organization established in 1983 by leaders of rare-disease patient organizations to represent all Americans affected by rare diseases. NORD provides programs of advocacy, education, research and patient/family services. We work closely with approximately 200 member organizations representing people with specific rare diseases. NORD has offices in Boston; Danbury, Conn.; and Washington, D.C. Learn more about NORD at http://www.rarediseases.org.

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at http://www.diahome.org.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11123786.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. After Taking Diabetes Drug Actos for Nearly Seven Years, Florida Man Developed Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
2. Contract Research Organization WCCT Global Announces Acquisition of Early Phase Ophthalmology and Aesthetics Capabilities
3. Medicaid pays for nearly half of all births in the United States
4. JCI early table of contents for Sept. 9, 2013
5. KORT Physical Therapy and Healthcare Reform: Early Intervention Drives Costs Down for Patients, Insurance Companies
6. Covance and the Indiana CTSI to collaborate on early clinical research
7. New method for early detection of colon cancer
8. Diet Doc Medical Weight Loss Plans Now Helps Women Lose Weight Fast Before Early Pregnancy to Reduce Risks of Premature Death for their Children
9. Diet Doc Weight Loss Plans Reveals New Fat Loss Diet Pills to Eliminate Fat Before Early Pregnancy Weight Can Affect Future Offspring
10. Early Detection Services at Dedicated Breast Center
11. New screening strategy may catch ovarian cancer at early stages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through ... Dermatology Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. ... the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company ...
(Date:2/11/2016)... Diego, CA (PRWEB) , ... February 11, 2016 , ... ... which was held in San Diego, CA, on February 6th & 7th, 2016 according ... combine for those who were not invited to the NFL’s combine in Indianapolis,” says ...
(Date:2/11/2016)... ... 11, 2016 , ... The book, “Computers Should Just Work!”, provides a basic, ... your IT consultant before signing a contract and how to spot an incompetent or ... relying heavily on e-mail and technology, it’s more important than ever to make sure ...
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of ... Round Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian ... Billy Cundiff. , “We are honored to support a promising young investigator from Dr. ...
(Date:2/10/2016)... Culver City, California (PRWEB) , ... February 10, ... ... Molecular Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will ... The theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  Oxis International Inc. (OTC/QB: OXIS) announced today that ... a "clinical trial triumph" after one of the first ... remission. Daniel Vallera , a research ... --> Daniel Vallera , a research ... --> An article on the University ...
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk ... technology, today announced the launch of LexisNexis ... solution that helps improve and optimize the quality ... of performance using severity-adjusted scores. By measuring provider ... critical solution to deliver better outcomes, improve the ...
(Date:2/10/2016)... AKIVA, Israel , February 10, 2016 ... a leader in the field of cartilage repair, announces ... February 5, 2016. The $15 million investment was led ... Chinese pharmaceutical manufacturer, and was joined by existing Regentis ... Holdings and both the Technion Research & Development Foundation ...
Breaking Medicine Technology: